Metabolic HealthSGLT2 Inhibitors Show Lower Self-Harm Risk in Type 2 Diabetes Study
A study using health records from Shenzhen, China, linked SGLT2 inhibitors, a class of diabetes medications, to lower self-harm risk compared with two other diabetes drug classes. Among patients starting SGLT2 or DPP-4 inhibitors, self-harm was recorded in 0.66% versus 1.05% over a median follow-up of 1.85 years. After statistical adjustment, SGLT2 inhibitors were associated with a 14% lower rate of self-harm over time. A separate comparison with GLP-1 receptor agonists found a 24% lower adjusted rate, although that finding was less consistent in additional analyses. These results offer reassurance about medication safety, not proof that SGLT2 inhibitors prevent self-harm. Patients should not change treatment based on this study alone. The research was observational, and this summary is based only on the abstract.
